What is claimed is:

- 1. A method of treating a human suffering from a disorder associated with dyslipidemia, said method comprising administering to the subject an effective amount of non-human animal ApoA-I protein.
- 2. The method of Claim 1 wherein the disorder associated with dyslipidemia is hypercholesterolemia.
- 3. The method of Claim 1 wherein the disorder associated with dyslipidemia is cardiovascular disease.
- 4. The method of Claim 1 wherein the disorder associated with dyslipidemia is atherosclerosis.
- 5. The method of Claim 1 wherein the disorder associated with dyslipidemia is restenosis.
- 6. The method of Claim 1 wherein the disorder associated with dyslipidemia is HDL or ApoA-I deficiency.
- 7. The method of Claim 1 wherein the disorder associated with dyslipidemia is hypertriglyceridemia.
- 8. A method of treating a subject suffering from an infection, said method comprising administering to the subject an effective amount of non-human animal ApoA-I protein.
- 9. The method of Claim 8 wherein the infection is bacterial.
- 10. The method of Claim 9 wherein the infection is septic shock.
- 11. The method of Claim 8 wherein the infection is viral.
- 12. The method of Claim 11 wherein the virus is influenza.
- 13. The method of Claim 11 wherein the virus is human immunodeficiency virus.
- 14. The method of Claim 11 wherein the virus is cytomegalovirus.

- 15. The method of Claim 11 wherein the virus is herpes simplex virus.
- 16. A pharmaceutical composition comprising non-human animal ApoA-I protein and a pharmaceutically acceptable carrier, excipient or diluent.
- 17. A non-human animal ApoA-I protein-lipid complex comprising non-human animal ApoA-I protein and a lipid.
- 18. A pharmaceutical composition comprising a non-human animal ApoA-I protein-lipid complex.
- 19. The composition of Claim 18 wherein the lipid is sphingomyelin.
- 20. The composition of Claim 19 which is in the form of a lyophilized powder.
- 21. The composition of Claim 19 which is in the form of a solution.
- 22. The method of Claim 1 or 8 wherein said subject is a human.
- 23. The method of Claim 1 or 8 wherein the non-human animal ApoA-I protein is bovine.
- 24. The method of Claim 1 or 8 wherein the non-human animal ApoA-I protein is from chickens.
- 25. The method of Claim 1 or 8 wherein the non-human animal ApoA-I protein is from turkeys.
- 26. The method of Claim 1 or 8 wherein the non-human animal ApoA-I protein is from pigs.
- 27. The method of Claim 1 or 8 wherein about 0.5 mg/kg to about 100 mg/kg of the non-human animal ApoA-I protein is administered to said subject.
- 28. A method of administering the composition of Claim 26 wherein the composition is administered orally.
- 29. The method of Claim 26 wherein the composition is administered intravenously.
- 30. The method of Claim 26 wherein the composition is administered by inhalation.

- 31. The method of Claim 26 wherein the composition is administered once daily.
- 32. The method of Claim 26 wherein the composition is administered twice daily.
- 33. The method of Claim 26 wherein the composition is administered three times daily.
- 34. The method of Claim 26 wherein the composition is administered four times daily.
- 35. The method of Claim 26 wherein the composition is administered about once weekly.
- 36. The method of Claim 26 wherein the composition is administered about once monthly.
- 37. The method of Claim 26 wherein the composition is administered about every six months.
- 38. The method of Claim 26 wherein the composition is administered about once weekly for one month.